Abstract:Objective To evaluate the efficacy and safety of combination therapy of tamsulosin and solifenacin for benign prostatic hyperplasia ( BPH ) with overactive bladder ( OAB ).Methods 82 patients with OAB and coexisting BPH were randomly divided into tamsulosin group ( n = 38 ) and combination group ( n = 44). The ages were from 50 to 75 y ( averaged, 56.8 ± 8.6). Inclusion criteria: the mean frequency of micturition ≥8 times per day, the frequency of nocturia ≥2 times per day, voiding volume ＜200 ml each time; for the overactive bladder symptom score ( OA BSS), the 3 rd score ＞ 2, total score ＞ 3. The tamsulosin group accepted tamsulosin 0.2 mg once daily, the combination group accepted tansulouxin 0.2 mg and solifenacin 0.2 mg once daily. Both groups were maintained the corresponding therapy for 12 weeks.The international prostate symptom score (IPSS), Qmax, residual urine volume, OAB score and adverse reactions were recorded.Results The values of IPSS ( 19.5 ±2.2 vs 15.6 ±2.4, P =0.027), the voiding symptom score ( 15.6 ± 2.4 vs 3.4 ± 1. 7, P = 0. 022) and Qmax ( 13.7 ± 3.8 vs 16.6 ± 4.1, P = 0. 034 )improved significantly after treatment in tamsulosin group ( P ＜ 0. 05 ). The values of IPSS ( 19.7 ± 2.3 vs 9.7 ± 3.0, P ＜0. 001), the storage symptom score (13.8 ± 1.9 vs 5.6 ± 1.6, P ＜0. 001 ), OABSS (10.3 ±1.8 vs 5.3 ±1.3, P ＜0.001) and Qmax(14.1 ±4.1 vs 17.2 ±3.5, P=0.027) also improved significantly after treatment in combination group ( P ＜ 0. 05 ). The values of IPSS ( 9.7 ± 3.0 vs 15.6 ±2.4, P ＜ 0.001 ), the storage symptom score (5.6 ± 1.6 vs 12.0 ± 1.6, P ＜ 0.001 ) and OABSS ( 5.3 ±1.3 vs 9.7 ± 2.7, P ＜ 0. 001 ) improved significantly in combination group than those in tamsulosin group ( P ＜0.001 ). There were no difference between two groups in values of the voiding symptom score, Qmax and residual urine volume ( P ＞ 0.05 ). The incidences of adverse reactions in tamsulosin group and combination group were 7.9％ (3/38) and 20.5％ (9/44) without significant difference. There was no acute urinary retention in both groups.Conclusions It is effective and safe for patients with BPH and OAB to accept combination therapy of tamsulosin and solifenacin.

A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Trial

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study

A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth

A comparative study of two means of simultaneous treatment for benign prostate hyperplasia and bladder stone

Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case-control study

Clinical Comparison of Selective and Non-Selective Alpha 1A-Adrenoceptor Antagonists for Bladder Outlet Obstruction Associated with Benign Prostatic Hyperplasia: Studies on Tamsulosin and Terazosin in Chinese Patients. the Chinese Tamsulosin Study Group.

Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Doxazosin Gastrointestinal Therapeutic System Versus Tamsulosin for the Treatment of Benign Prostatic Hyperplasia: a Study in Chinese Patients.

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis

Comparison between combination of tamsulosin and Pentoxifylline versus tamsulosin alone in the treatment of lower urinary tract symptoms due to benign prostate hyperplasia: A preliminary study

Observation on Curative Efficacy of Tamsulosin Hydrochloride Sustained-Release Capsules Combined with Finasteride Tablets in the Treatment of Benign Prostatic Hyperplasia

Combination of Tamsulosin and Tolterodine Alleviates Refractory Lower Urinary Tract Symptoms in Male Patients

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Clinical Study of Combination Therapy of Tamsulosin and Solifenacin for Benign Prostatic Hyperplasia with Overactive Bladder

Efficacy and Tolerability of Doxazosin Gastro-Intestinal Therapeutic System Versus Tamsulosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia